RxDoctor Payments Data

Kelley Scott

Family · Toronto, OHNPI 1396116109

Payments from drug & device makers

$6,918in general payments, 2019–2025

Across 422 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$799
  • Pfizer$477
  • Lilly USA, LLC$452
  • Novo Nordisk$364
  • Daiichi Sankyo Inc.$349
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$6,897100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,918 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$25,886
Medicare patients
180
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$122,888
EliquisApixaban103$81,755
VraylarCariprazine Hcl30$50,933
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$25,736
XareltoRivaroxaban21$19,588
TrulicityDulaglutide20$19,413
FarxigaDapagliflozin Propanediol21$17,273
MounjaroTirzepatide13$16,923
Bevespi AerosphereGlycopyrrolate/Formoterol Fum24$10,160
LinzessLinaclotide20$9,670
Sirolimus12$9,202
ZtlidoLidocaine12$8,678
Tresiba Flextouch U-200Insulin Degludec11$8,405
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$7,481
MovantikNaloxegol Oxalate15$6,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$364$122,88888 claims
PfizerEliquis$477$81,755103 claims
AbbVieVraylar, Linzess$1,209$60,60250 claims
Lilly USA, LLCTrulicity, Mounjaro$452$36,33633 claims
GSKTrelegy Ellipta, Anoro Ellipta$157$33,21746 claims
AstraZenecaFarxiga, Bevespi Aerosphere$799$27,43345 claims
Johnson & JohnsonXarelto$251$19,58821 claims
Scilex Pharmaceuticals Inc.Ztlido$88$8,67812 claims
Almatica Pharma LLCSertraline Hcl$13$899152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Toronto

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →